ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2393

Improving Clinical Outcomes In SLE Arthritis Trials: Post-Hoc Analysis Of A Prospective Intervention Study

Samuel Wood1, Khaled Mahmoud2, Md Yuzaiful Md Yusof2, Philip Conaghan2, Elizabeth Hensor2 and Ed Vital3, 1University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, 2University of Leeds, Leeds, United Kingdom, 3University of Leeds, Leeds, England, United Kingdom

Meeting: ACR Convergence 2025

Keywords: clinical trial, Musculoskeletal Examination, Outcome measures, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Musculoskeletal (MSK) manifestations of SLE are the most frequently assessed domain in clinical trials. Optimal MSK assessment is contested; candidates include the binary or ordinal SLEDAI and BILAG, tender joint count (TJC), swollen joint count (SJC) and “active” joint counts, (either tender or swollen, or both).Ultrasound studies in SLE have identified imaging-only synovitis, such that the BILAG A/B criterion has a sensitivity of just 56% for US synovitis.Our aim was to assess sensitivity and specificity of a set of candidate joint counts against US synovitis, as well as patient and US defined response to therapy.

Methods: We performed a post-hoc analysis of a multi-centre study [USEFUL; PMID: 33792659]. Patients with inflammatory arthralgia were assessed clinically and using US at 0, 2 and 6 weeks following single-dose intra-muscular glucocorticoid therapy.Candidate joint sets were defined as: 68 TJC and SJC, 28 TJC and SJC, or 24 TJC and SJC (MCPs, PIPs, elbows, wrists). Joint counts were compared with weighted scatter plots and intraclass correlation coefficients (ICCs).Participant-reported change was measured using a Likert scale (-7 to 7). For US response, changes in number of ‘active’ joints (grey scale ≥2 and/or power Doppler ≥1) were calculated. Spearman rank correlation measured associations between changes in the candidate joint counts, participant-reported changes and changes in the number of US active joints. Associations are also reported for the composite lupus arthritis and MSK disease activity score (LAMDA) (Table 2).

Results: Of 133 patients, 95% female and 62% European ancestry, 63% had ≥1 SJC at baseline. TJC and SJC had poor sensitivity (50.7% and 41.6% respectively), and TJC had lower specificity than SJC (60.7% and 91.4% respectively)(Table 1). Active “either” and active “both” almost exactly matched TJC and SJC respectively (Figure 1a-h). In joint-by-joint analysis the most commonly swollen joints were MCPs 2-5.Tenderness was most common in MCP 2 and 3, wrist, shoulder and knee. Reduced joint counts were more strongly correlated with US-defined response than full joint counts (Figure 1i) but not with participant-defined response. Changes in TJCs correlated with participant-defined response and changes in SJCs with US-defined response but not vice-versa. LAMDA was modestly correlated with both response definitions.

Conclusion: (1) TJC and SJC have limited sensitivity for imaging-detected synovitis, but SJC has high specificity. (2) Active ‘either’ and ‘both’ joint counts almost exactly match TJC and SJC respectively and are therefore redundant. (3) Diagnostic accuracy of clinical assessment varies by joint area; shoulders and knees likely contribute little to assessment of joint inflammation and often have non-inflammatory pathology. (4) SJC is the most responsive measure of objective synovitis; SJC24 is the most responsive set for US response, but is not correlated with participant-defined response. Given the relative insensitivity of SJC, and importance of patient defined response, the composite measure, LAMDA may be optimal in RCTs. Future work will evaluate these variables in randomised trials and define inclusion and response thresholds.

Supporting image 1Table 1. Sensitivity and specificity of clinical assessment in the detection of ultrasound-detected synovitis.

Supporting image 2Figure 1 a-h: Weighted scatter plots of joint counts versus active definitions at baseline. Intraclass correlation coefficients (ICCs) displayed; i: Associations between changes in joint assessments and participant- or US-defined response at 6 weeks.

Supporting image 3Components of the composite lupus arthritis and MSK disease activity (LAMDA) score.


Disclosures: S. Wood: None; K. Mahmoud: None; M. Md Yusof: GlaxoSmithKlein(GSK), 1, Novartis, 1, 6, UCB, 2, 6; P. Conaghan: AbbVie/Abbott, 2, 6, Alfasigma, 2, 6, Eli Lilly, 2, 6, Eupraxia, 2, 6, Formation Bio, 2, 6, Galapagos, 2, Genascence, 2, 6, Grunenthal, 2, 6, Janssen, 2, Kolon TissueGene, 2, 6, Levicept, 2, 6, Medipost, 2, Moebius Medical, 2, 6, Novartis, 2, 6, Orion, 2, 6, Pacira, 2, 6, Sandoz, 2, 6, Stryker, 2, 6, Takeda, 2, 6; E. Hensor: None; E. Vital: AbbVie, 2, 6, Alpine, 2, AstraZeneca, 2, 5, 6, Aurinia, 2, 6, BMS, 2, 6, Eli Lilly, 2, 6, Idorsia, 6, ILTOO Pharma, 6, Merck, 2, 6, Novartis, 2, 6, 12, Paid instructor, Otsuka, 2, 6, Pfizer, 2, 6, Roche, 2, 5, 6, Sandoz, 5, UCB, 2, 6.

To cite this abstract in AMA style:

Wood S, Mahmoud K, Md Yusof M, Conaghan P, Hensor E, Vital E. Improving Clinical Outcomes In SLE Arthritis Trials: Post-Hoc Analysis Of A Prospective Intervention Study [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/improving-clinical-outcomes-in-sle-arthritis-trials-post-hoc-analysis-of-a-prospective-intervention-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/improving-clinical-outcomes-in-sle-arthritis-trials-post-hoc-analysis-of-a-prospective-intervention-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology